[Promise of immunotherapy of the chronic myeloid leukaemia].
Because of the presence of unique antigens, chronic myeloid leukaemia (CML) represents an appealing target for immunotherapy. The progress achieved in the fields of gene therapy, tumour immunology and vaccinology offers a wide spectrum of methods that could be utilized for the development of therapeutic vaccines against CML. Experience obtained in several clinical studies with peptide-based vaccines have made it clear that it is possible to induce specific immune reactivity; however, its clinical efficacy has been low if any. Studies in mouse systems, which are under way, should be helpful in defining the optimal strategy for immunizing human subjects against bcr-abl positive cells. The author adduces some advantages, but also the limitations, of animal models for this purpose. He also comments on the possibility that the bcr-abl-based therapeutic vaccines might be found ineffective and proposes procedures how to deal with the problem.
Vonka
V
V
Ustav hematologie a krevní transfuze, Praha. vonka@uhkt.cz
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*
D019496:Cancer Vaccines